Summary
This 2018 laboratory study investigated iron chelation as a potential therapeutic approach in clear cell renal cell carcinoma, examining whether suppressive effects on cancer cell growth depend on VHL inactivation—a common genetic alteration in this cancer type. The findings, as suggested by the title, indicate that iron chelation exerts anti-proliferative effects through mechanisms linked to dysregulated iron and hypoxia-inducible factor (HIF) signalling in VHL-deficient cells. The work contributes to mechanistic understanding of how iron metabolism intersects with the HIF pathway in ccRCC pathogenesis.
UK applicability
This is a fundamental laboratory study of cancer cell biology with no direct farming or food systems application. Its relevance to UK policy or clinical practice would be indirect—potentially informing future oncology therapeutics—but lies outside Vitagri's primary focus on farming systems, soil health, and nutrition-related health outcomes in food contexts.
Key measures
Cellular viability, proliferation, and survival markers in ccRCC cells with differing VHL status; iron metabolism and HIF signalling pathway activity under iron-chelated conditions.
Outcomes reported
The study examined suppressive effects of iron chelation on clear cell renal cell carcinoma (ccRCC) cells in laboratory conditions, with particular focus on whether therapeutic efficacy depends on VHL inactivation status.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.